EXODUS H-300 Automated Exosome Isolation System
| Brand | EXODUS |
|---|---|
| Origin | Guangdong, China |
| Manufacturer Type | Authorized Distributor |
| Country of Origin | China |
| Model | H-300 |
| Price | Upon Request |
| Temperature Control Range | 2–8 °C |
| Sample Processing Volume | 10 µL – 50 mL |
| Sterilization Method | Built-in UV-C Germicidal Irradiation (254 nm) |
| Operating Principle | Integrated Negative-Pressure Oscillation (NPO) and Dual-Coupled Harmonic Oscillation (HO) applied to Nanoporous Ultrafiltration Chip |
| Throughput | 50 mL per hour |
Overview
The EXODUS H-300 Automated Exosome Isolation System is an integrated benchtop platform engineered for reproducible, label-free isolation of extracellular vesicles (EVs), specifically exosomes (30–150 nm), from diverse biological matrices including plasma, serum, urine, cell culture supernatant, and cerebrospinal fluid. It employs a dual-physical separation principle—combining controlled negative-pressure oscillation (NPO) with precisely tuned dual-coupled harmonic oscillation (HO)—to drive sample flow across proprietary nanoporous ultrafiltration chips. This non-centrifugal, non-immunoaffinity method avoids antibody bias, polymer contamination, or ultracentrifugation-induced aggregation, preserving native exosome morphology, surface marker integrity (e.g., CD63, CD81, TSG101), and functional cargo (miRNA, proteins, lipids). Designed for GLP-aligned workflows, the system maintains sample integrity through continuous temperature stabilization at 2–8 °C during processing, minimizing enzymatic degradation and vesicle fusion.
Key Features
- Automated, walk-away operation with pre-programmed protocols for 7 common biofluid types—no manual pipetting or protocol optimization required.
- Nanoporous ultrafiltration chip architecture with defined pore size distribution (nominal cutoff: 100 nm), validated for >95% exosome recovery and >99.2% removal of soluble proteins (e.g., albumin, IgG) and free nucleic acids.
- Integrated UV-C (254 nm) chamber providing ≥3-log reduction of airborne and surface-borne microbial load between runs—critical for longitudinal studies and multi-user lab environments.
- Real-time pressure monitoring and adaptive oscillation frequency modulation ensure consistent transmembrane flux and prevent chip clogging across viscosity-variable samples (e.g., heparinized plasma vs. ascites fluid).
- Compact footprint (W320 × D540 × H420 mm) and low power consumption (<120 W) enable deployment in biosafety cabinets or shared core facilities without HVAC recalibration.
Sample Compatibility & Compliance
The EXODUS H-300 accommodates input volumes from 10 µL (e.g., microdissected tissue lysate) to 50 mL (e.g., pooled plasma), supporting both discovery-scale and translational batch processing. All wetted components—including chip housings, fluidic manifolds, and collection tubes—are manufactured from medical-grade, DNase/RNase-free polypropylene compliant with ISO 10993-5 cytotoxicity standards. The system meets IEC 61000-4-2 (ESD immunity) and IEC 61326-1 (EMC for laboratory equipment). While not FDA-cleared as an IVD device, its operational parameters align with MISEV2023 minimal experimental requirements for EV isolation, and raw output data (pressure logs, cycle timestamps, temperature traces) are timestamped and exportable in CSV/JSON format for audit trail reconstruction under 21 CFR Part 11–compatible LIMS integration.
Software & Data Management
The embedded control software (v3.2.x) provides role-based user access (Operator, Supervisor, Administrator), encrypted local storage of run metadata (including chip lot ID, calibration date, operator ID), and automated generation of QC reports (recovery yield estimate, turbidity index, protein-to-exosome ratio proxy). Exported datasets include full sensor time-series (temperature, pressure, oscillation amplitude) synchronized to process stages. Raw data files adhere to MIAME-compliant naming conventions and support direct import into downstream analysis platforms such as ExoCarta, Vesiclepedia, or custom Python/R pipelines via open API endpoints (RESTful JSON over HTTPS).
Applications
- Biomarker discovery: Isolation of intact exosomes for mass spectrometry–based proteomics and small RNA sequencing with reduced background interference.
- Therapeutic development: Production of clinical-grade exosome batches for loading with siRNA, mRNA, or chemotherapeutics—validated by dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA) post-isolation.
- Functional assays: Recovery of bioactive exosomes retaining membrane fluidity and receptor engagement capacity, enabling reliable in vitro uptake studies (e.g., confocal imaging with PKH67 labeling) and in vivo biodistribution tracing.
- Longitudinal monitoring: Standardized isolation across multi-center trials where inter-operator variability must be minimized—demonstrated in published studies on NSCLC and early-stage Alzheimer’s CSF profiling.
FAQ
What is the recommended maintenance schedule for the nanoporous ultrafiltration chips?
Chips are single-use and supplied sterile in sealed pouches; no cleaning or reuse is permitted. Each chip lot undergoes batch validation for pore size distribution (SEM + TEM cross-check) and endotoxin levels (<0.03 EU/mL).
Can the system process viscous samples such as synovial fluid or pleural effusions?
Yes—via optional viscosity-adaptive mode (enabled in Supervisor mode), which dynamically adjusts HO frequency and NPO ramp rate based on real-time pressure feedback. Validation data available upon request.
Is the UV-C sterilization cycle validated against specific microbial strains?
Yes—third-party testing confirms ≥3-log reduction of Staphylococcus aureus, Escherichia coli, and Candida albicans after 15-minute exposure at 1.2 mW/cm² irradiance.
Does the system support integration with LIS or ELN platforms?
Yes—via configurable HL7 v2.5 and ASTM E1384-compliant interfaces; SFTP-based secure file transfer for QC reports and sensor logs is standard.
